For Our Patients
Clinical Trials and Research
Enrolling in
a Study
Interested in Enrolling?
Thank you for your interest in participating in one of our clinical trials. These studies offer eligible new patients the opportunity to receive the latest, most advanced treatments for vitreoretinal conditions — all under the expert care of our dedicated clinical research team.
Currently Enrolling Studies
Last updated on Monday, November 3, 2025
If you’re a new patient and would like to be considered for enrollment, please click Enroll in this Study to send us an email. Be sure to include: Your full name, the reason you're interested in participating, the office location where you currently receive treatment. Our team will respond within 48–72 hours.
Below is a list of studies currently open for enrollment:
RESEARCH LOCATION: ORLANDO
Clinical Trial for Neovascular Age-Related Macular Degeneration (nAMD)
Protocol ID: RTE888-E001 (NOVA)
ClinicalTrials.gov ID: NCT05769153
Sponsor: Alcon Research
This trial is testing AR-14034 Sustained Release (SR), a tiny implant that slowly releases medicine into the eye for patients with wet AMD. The goal is to determine safety, effectiveness, and whether it reduces the need for frequent eye injections compared to standard treatment (https://www.drugs.com/mtm/aflibercept.html).
Clinical Trial for Geographic Atrophy (GA)
Protocol ID: ONL1204-GA-002 (Galaxy)
ClinicalTrials.gov ID: NCT05800659
Sponsor: ONL Therapeutics
This study evaluates a new therapy for Geographic Atrophy, an advanced form of dry AMD that leads to vision loss. The trial aims to assess whether the treatment can slow disease progression and preserve vision.
Clinical Trial for Macular Neovascularization Secondary to AMD
Protocol ID: 4D-150-C003 (4Front-1)
ClinicalTrials.gov ID: NCT06864988
Sponsor: 4D Molecular Therapeutics
This Phase 3 trial tests 4D-150, a gene therapy delivered as a single eye injection to treat macular https://www.aao.org/eye-health/diseases/neovascularization caused by AMD. It compares 4D-150 to https://www.drugs.com/mtm/aflibercept.html to see which treatment works better and lasts longer.
Clinical Trial for Diabetic Macular Edema
Protocol ID: EYE-RES-103 (Barolo)
ClinicalTrials.gov ID: NCT06115762
Sponsor: EyeBio
This trial investigates a novel therapy for Diabetic Macular Edema, a complication of diabetes that causes vision-threatening swelling in the retina. The study evaluates safety and efficacy compared to current standard treatments.
Clinical Trial for Geographic Atrophy Secondary to AMD
Protocol ID: R3918-AMD-2326 (Sienna)
ClinicalTrials.gov ID: NCT06171743
Sponsor: Regeneron Pharmaceuticals
This trial focuses on Geographic Atrophy, testing whether the investigational drug can slow retinal degeneration and preserve vision in patients with advanced AMD.
Clinical Trial for Neovascular Age-Related Macular Degeneration (nAMD)
Protocol ID: M24-528 (Achieve)
ClinicalTrials.gov ID: NCT06171756
Sponsor: AbbVie / RegnexBio
This study evaluates a new treatment for nAMD, aiming to improve visual outcomes and reduce the frequency of injections compared to existing therapies.
RESEARCH LOCATION: JACKSONVILLE
Clinical Trial for Macular Neovascularization Secondary to AMD
Protocol ID: 4D-150-C003 (4Front-1)
ClinicalTrials.gov ID: NCT06864988
Sponsor: 4D Molecular Therapeutics
This Phase 3 trial tests 4D-150, a gene therapy delivered as a single eye injection to treat macular https://www.aao.org/eye-health/diseases/neovascularization caused by AMD. It compares 4D-150 to https://www.drugs.com/mtm/aflibercept.html to see which treatment works better and lasts longer.
Clinical Trial for Diabetic Retinopathy of Non-Proliferative Type (NPDR)
Protocol ID: 1436-0007 (CRIMSON)
ClinicalTrials.gov ID: NCT06171744
Sponsor: Boehringer Ingelheim Pharmaceuticals Inc
This trial tests a new therapy for NPDR, a stage of diabetic retinopathy that can lead to vision loss. The goal is to prevent progression to proliferative disease and reduce complications.
Clinical Trial for Diabetic Retinopathy of Non-Proliferative Type (NPDR)
Protocol ID: VX01-DR-201
ClinicalTrials.gov ID: NCT06171745
Sponsor: Vantage Biosciences Ltd
This study evaluates a novel approach to treating NPDR, aiming to preserve vision and prevent disease progression.
Clinical Trial for Diabetic Macular Edema
Protocol ID: GR43828 (THAMES)
ClinicalTrials.gov ID: NCT06171746
Sponsor: Genentech, Inc.
This trial investigates a new therapy for Diabetic Macular Edema, comparing its effectiveness and durability to current standard treatments.
Clinical Trial for Neovascular Age-Related Macular Degeneration (nAMD)
Protocol ID: RTE888-E001 (NOVA)
ClinicalTrials.gov ID: NCT05769153
Sponsor: Alcon Research
This trial is testing AR-14034 Sustained Release (SR), a tiny implant that slowly releases medicine into the eye for patients with wet AMD. The goal is to determine safety, effectiveness, and whether it reduces the need for frequent eye injections compared to standard treatment (https://www.drugs.com/mtm/aflibercept.html).
Clinical Trial for Geographic Atrophy Secondary to AMD
Protocol ID: R3918-AMD-2326 (Sienna)
ClinicalTrials.gov ID: NCT06171743
Sponsor: Regeneron Pharmaceuticals
This trial focuses on Geographic Atrophy, testing whether the investigational drug can slow retinal degeneration and preserve vision in patients with advanced AMD.
For more information about clinical trials or if you should have any questions, please feel free to contact us.
